Protheroe A - Search Results

1

Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinoma.

Fairfax BP, Pratap S, Roberts IS, Collier J, Kaplan R, Meade AM, Ritchie AW, Eisen T, Macaulay VM, Protheroe A. Fairfax BP, et al. Among authors: protheroe a. BMC Cancer. 2012 Dec 11;12:590. doi: 10.1186/1471-2407-12-590. BMC Cancer. 2012. PMID: 23231599 Free PMC article.

2

A multicentre phase II trial of bryostatin-1 in patients with advanced renal cancer.

Madhusudan S, Protheroe A, Propper D, Han C, Corrie P, Earl H, Hancock B, Vasey P, Turner A, Balkwill F, Hoare S, Harris AL. Madhusudan S, et al. Among authors: protheroe a. Br J Cancer. 2003 Oct 20;89(8):1418-22. doi: 10.1038/sj.bjc.6601321. Br J Cancer. 2003. PMID: 14562010 Free PMC article. Clinical Trial.

3

The safety and feasibility of extracorporeal high-intensity focused ultrasound (HIFU) for the treatment of liver and kidney tumours in a Western population.

Illing RO, Kennedy JE, Wu F, ter Haar GR, Protheroe AS, Friend PJ, Gleeson FV, Cranston DW, Phillips RR, Middleton MR. Illing RO, et al. Among authors: protheroe as. Br J Cancer. 2005 Oct 17;93(8):890-5. doi: 10.1038/sj.bjc.6602803. Br J Cancer. 2005. PMID: 16189519 Free PMC article. Clinical Trial.

4

The VHL tumor suppressor inhibits expression of the IGF1R and its loss induces IGF1R upregulation in human clear cell renal carcinoma.

Yuen JS, Cockman ME, Sullivan M, Protheroe A, Turner GD, Roberts IS, Pugh CW, Werner H, Macaulay VM. Yuen JS, et al. Among authors: protheroe a. Oncogene. 2007 Oct 4;26(45):6499-508. doi: 10.1038/sj.onc.1210474. Epub 2007 May 7. Oncogene. 2007. PMID: 17486080

5

The type 1 insulin-like growth factor receptor is over-expressed in bladder cancer.

Rochester MA, Patel N, Turney BW, Davies DR, Roberts IS, Crew J, Protheroe A, Macaulay VM. Rochester MA, et al. Among authors: protheroe a. BJU Int. 2007 Dec;100(6):1396-401. doi: 10.1111/j.1464-410X.2007.06931.x. Epub 2007 Jul 23. BJU Int. 2007. PMID: 17645417

6

The type 1 insulin-like growth factor receptor pathway.

Chitnis MM, Yuen JS, Protheroe AS, Pollak M, Macaulay VM. Chitnis MM, et al. Clin Cancer Res. 2008 Oct 15;14(20):6364-70. doi: 10.1158/1078-0432.CCR-07-4879. Clin Cancer Res. 2008. PMID: 18927274 Review.

7

Validation of the type 1 insulin-like growth factor receptor as a therapeutic target in renal cancer.

Yuen JS, Akkaya E, Wang Y, Takiguchi M, Peak S, Sullivan M, Protheroe AS, Macaulay VM. Yuen JS, et al. Mol Cancer Ther. 2009 Jun;8(6):1448-59. doi: 10.1158/1535-7163.MCT-09-0101. Epub 2009 Jun 9. Mol Cancer Ther. 2009. PMID: 19509240

8

An adult Xp11.2 translocation renal carcinoma showing response to treatment with sunitinib.

Pwint TP, Macaulay V, Roberts IS, Sullivan M, Protheroe A. Pwint TP, et al. Among authors: protheroe a. Urol Oncol. 2011 Nov-Dec;29(6):821-4. doi: 10.1016/j.urolonc.2009.10.007. Epub 2009 Dec 4. Urol Oncol. 2011. PMID: 19962921

9

Type 1 insulin-like growth factor receptor translocates to the nucleus of human tumor cells.

Aleksic T, Chitnis MM, Perestenko OV, Gao S, Thomas PH, Turner GD, Protheroe AS, Howarth M, Macaulay VM. Aleksic T, et al. Cancer Res. 2010 Aug 15;70(16):6412-9. doi: 10.1158/0008-5472.CAN-10-0052. Cancer Res. 2010. PMID: 20710042 Free PMC article.

10

Blastic plasmacytoid dendritic cell neoplasm presenting as a renal mass.

Prematilleke I, Mohan V, Roberts I, Protheroe A, Gatter K. Prematilleke I, et al. Among authors: protheroe a. Histopathology. 2011 Oct;59(4):799-801. doi: 10.1111/j.1365-2559.2011.03953.x. Epub 2011 Sep 21. Histopathology. 2011. PMID: 21939455 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

153 results

Search Page